{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.60","upperLimit":"5.22","value":"2.99"},{"groupId":"OG001","lowerLimit":"1.97","upperLimit":"7.36","value":"3.12"},{"comment":"Insufficient number of events to calculate upper limit of the CI using the K-M method.","groupId":"OG002","lowerLimit":"0.56","upperLimit":"NA","value":"6.33"},{"groupId":"OG003","lowerLimit":"23.95","upperLimit":"23.95","value":"23.95"},{"groupId":"OG004","lowerLimit":"0.76","upperLimit":"24.02","value":"14.23"},{"comment":"Insufficient number of events to calculate median and upper limit of the CI using the K-M method.","groupId":"OG005","lowerLimit":"5.65","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"description":"Event-free survival is from JCAR017 infusion to death from any cause, progressive disease, or starting a new anticancer therapy. If a participant did not have an EFS event prior to data cutoff, EFS was censored at last disease assessment.\n\nProgressive disease (PD):\n\n* Target nodes/nodal masses: PPD progression.\n* Extranodal lesion: LDi \\> 1.5 cm and increase by ≥ 50% from PPD nadir.\n* Splenomegaly: \\> 50% of prior increase from baseline or by at least 2 cm from baseline.\n* Nonmeasured lesions: New or clear progression.\n* New lesions: Regrowth of previously resolved lesions.\n* Bone marrow: New or recurrent\n\nProgressive Disease (Cohort 5):\n\n* Brain imaging: \\> 25% increase in enhancing lesion from baseline or best response.\n* Eye Exam: Increased vitreous cell counts or progressive retinal or optic nerve infiltration.\n* New lesion or site of disease","dispersionType":"95% Confidence Interval","groups":[{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG000","title":"Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG001","title":"Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG002","title":"Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG003","title":"Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG004","title":"Cohort 5: Primary Central Nervous System Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG005","title":"Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting"}],"paramType":"MEDIAN","populationDescription":"All participants in the JCAR017 treated set.","reportingStatus":"POSTED","timeFrame":"From JCAR017 infusion to death due to any reason, progressive disease, or starting a new anticancer therapy (up to approximately 63 months).","title":"Event Free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"Months"}